Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13224* | 2021 |
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 M Baker, IR Mackenzie, SM Pickering-Brown, J Gass, R Rademakers, ... Nature 442 (7105), 916-919, 2006 | 2276 | 2006 |
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity S Weggen, JL Eriksen, P Das, SA Sagi, R Wang, CU Pietrzik, KA Findlay, ... Nature 414 (6860), 212-216, 2001 | 1855 | 2001 |
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo JL Eriksen, SA Sagi, TE Smith, S Weggen, P Das, DC McLendon, ... The Journal of clinical investigation 112 (3), 440-449, 2003 | 887 | 2003 |
Aβ42 is essential for parenchymal and vascular amyloid deposition in mice E McGowan, F Pickford, J Kim, L Onstead, J Eriksen, C Yu, L Skipper, ... Neuron 47 (2), 191-199, 2005 | 724 | 2005 |
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity S Weggen, JL Eriksen, SA Sagi, CU Pietrzik, V Ozols, A Fauq, TE Golde, ... Journal of Biological Chemistry 278 (34), 31831-31837, 2003 | 387 | 2003 |
A decade of modeling Alzheimer's disease in transgenic mice E McGowan, J Eriksen, M Hutton TRENDS in Genetics 22 (5), 281-289, 2006 | 385 | 2006 |
Substrate-targeting γ-secretase modulators TL Kukar, TB Ladd, MA Bann, PC Fraering, R Narlawar, GM Maharvi, ... Nature 453 (7197), 925-929, 2008 | 378 | 2008 |
Molecular pathogenesis of Parkinson disease JL Eriksen, Z Wszolek, L Petrucelli Archives of neurology 62 (3), 353-357, 2005 | 371 | 2005 |
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia R Rademakers, JL Eriksen, M Baker, T Robinson, Z Ahmed, SJ Lincoln, ... Human molecular genetics 17 (23), 3631-3642, 2008 | 351 | 2008 |
Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production T Kukar, MP Murphy, JL Eriksen, SA Sagi, S Weggen, TE Smith, T Ladd, ... Nature medicine 11 (5), 545-550, 2005 | 349 | 2005 |
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice S Le Corre, HW Klafki, N Plesnila, G Hübinger, A Obermeier, H Sahagún, ... Proceedings of the National Academy of Sciences 103 (25), 9673-9678, 2006 | 293 | 2006 |
Caught in the act: α-synuclein is the culprit in Parkinson's disease JL Eriksen, TM Dawson, DW Dickson, L Petrucelli Neuron 40 (3), 453-456, 2003 | 229 | 2003 |
Progranulin: normal function and role in neurodegeneration JL Eriksen, IRA Mackenzie Journal of neurochemistry 104 (2), 287-297, 2008 | 181 | 2008 |
Plaques, tangles, and memory loss in mouse models of neurodegeneration JL Eriksen, CG Janus Behavior genetics 37, 79-100, 2007 | 180 | 2007 |
Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP … S Weggen, JL Eriksen, SA Sagi, CU Pietrzik, TE Golde, EH Koo Journal of Biological Chemistry 278 (33), 30748-30754, 2003 | 177 | 2003 |
NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? S Weggen, M Rogers, J Eriksen Trends in pharmacological sciences 28 (10), 536-543, 2007 | 166 | 2007 |
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice T Kukar, S Prescott, JL Eriksen, V Holloway, MP Murphy, EH Koo, ... BMC neuroscience 8, 1-12, 2007 | 160 | 2007 |
Gene dosage and pathogenesis of Parkinson's disease JL Eriksen, S Przedborski, L Petrucelli Trends in molecular medicine 11 (3), 91-96, 2005 | 142 | 2005 |
Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology AT Dao, MA Zagaar, AT Levine, S Salim, JL Eriksen, KA Alkadhi Current Alzheimer Research 10 (5), 507-515, 2013 | 120 | 2013 |